Please assess the completion status of the following clinical trial:

Trial Title: Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of one of the following:~  * Acute lymphoblastic leukemia~    * Philadelphia chromosome (Bcr-abl) positive~   * Refractory to initial therapy OR recurrent following 1 induction therapy regimen with or without consolidation therapy and/or bone marrow transplantation~ * Blastic phase chronic myelogenous leukemia~    * Philadelphia chromosome (Bcr-abl) positive~   * Previously untreated OR recurrent or refractory following 1 induction therapy regimen with or without consolidation therapy including imatinib mesylate~* Must not be eligible for bone marrow transplant~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Eastern Cooperative Oncology Group (ECOG) 0-2~Life expectancy:~* At least 8 weeks~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin no greater than 2.0 times upper limit of normal (ULN)~* AST/ALT no greater than 2 times ULN~Renal:~* Creatinine no greater than 2.0 times ULN~* Creatinine clearance greater than 70 mL/min~Cardiovascular:~* No uncontrolled angina~* No New York Heart Association class III or IV heart disease~* No second degree heart block without pacemaker~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after study~* HIV negative~* No uncontrolled infection or other serious concurrent illness~* No peripheral neuropathy~* No potassium less than 3.0 or greater than 5.5 mEq/L that can not be corrected OR~* No magnesium less than 1.2 or greater than 2.5 mEq/L that can not be corrected~* Electrolyte imbalances must be corrected prior to study entry~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~* At least 28 days since prior chemotherapy~* At least 24 hours since prior hydroxyurea~* No prior arsenic trioxide~* No other concurrent cytotoxic chemotherapy except intrathecal chemotherapy for CNS leukemia~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 28 days since prior radiotherapy~* No concurrent radiotherapy including for palliation~Surgery:~* Not specified~Other:~* At least 14 days since prior imatinib mesylate~* No other concurrent investigational agents~* No concurrent amphotericin B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arsenic Trioxide Treatment (Type: EXPERIMENTAL): Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.

Based on this trial design, predict the completion outcome and termination type (if applicable).